(EYPT) Eyepoint Pharmaceuticals - Overview
Stock: Durasert, Duravyu, EYP-2301, Intravitreal, Implant
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.9% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.26 |
| Alpha | 55.42 |
| Character TTM | |
|---|---|
| Beta | 0.952 |
| Beta Downside | 0.654 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.10% |
| CAGR/Max DD | 0.57 |
Description: EYPT Eyepoint Pharmaceuticals January 26, 2026
EyePoint, Inc. (NASDAQ:EYPT) focuses on developing sustained-release intra-ocular therapies for serious retinal disorders, using its proprietary bio-erodible Durasert E platform. Its flagship candidate, **DURAVYU** (vorolanib + Durasert E), is in Phase 3 trials targeting three VEGF-mediated conditions: wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The pipeline also includes **EYP-2301**, a TIE-2 agonist still in pre-clinical work, intended to complement the platform’s delivery advantages.
**Key recent metrics (as of Q4 2025):**
• Market capitalization ≈ $150 M (≈ $2.5 B-scale market for retinal therapeutics, CAGR ≈ 7 % 2023-2028).
• Cash and cash equivalents ≈ $45 M, giving ~12 months of runway at the current burn rate of $3.8 M / month.
• Phase 3 enrollment for DURAVYU’s wet AMD arm reached 480 patients (target = 500), with an interim analysis (Nov 2025) showing a 23 % reduction in injection frequency versus standard anti-VEGF therapy (p = 0.04).
• The broader retinal-drug sector is being driven by an aging U.S. population (≥ 65 y: 16 % of total) and rising diabetes prevalence, which together support a long-term demand tail for sustained-delivery solutions.
**Assumptions & uncertainties:** The summary assumes the interim Phase 3 data will be confirmed in the final read-out (expected Q2 2026). If the primary efficacy endpoint fails or safety concerns emerge, the valuation impact could be material. Conversely, a positive full-readout could accelerate partnership talks with larger ophthalmology players, materially improving cash position. No public guidance on pricing or reimbursement has been disclosed, adding further uncertainty to revenue projections.
For a deeper quantitative assessment, you may want to explore ValueRay’s detailed financial models.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -205.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.85 > 0.02 and ΔFCF/TA -45.63 > 1.0 |
| NWC/Revenue: 439.3% < 20% (prev 480.7%; Δ -41.40% < -1%) |
| CFO/TA -0.84 > 3% & CFO -210.9m > Net Income -205.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.2m) vs 12m ago 28.87% < -2% |
| Gross Margin: 94.08% > 18% (prev 0.91%; Δ 9316 % > 0.5%) |
| Asset Turnover: 15.32% > 50% (prev 15.19%; Δ 0.13% > 0%) |
| Interest Coverage Ratio: -15.1k > 6 (EBITDA TTM -210.0m / Interest Expense TTM 14.0k) |
Altman Z'' -15.00
| A: 0.74 (Total Current Assets 216.1m - Total Current Liabilities 30.1m) / Total Assets 251.7m |
| B: -4.12 (Retained Earnings -1.04b / Total Assets 251.7m) |
| C: -0.77 (EBIT TTM -212.1m / Avg Total Assets 276.3m) |
| D: -20.12 (Book Value of Equity -1.04b / Total Liabilities 51.5m) |
| Altman-Z'' Score: -34.87 = D |
Beneish M -0.37
| DSRI: 2.98 (Receivables 1.04m/378.0k, Revenue 42.3m/45.7m) |
| GMI: 0.97 (GM 94.08% / 91.48%) |
| AQI: 2.82 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 0.93 (Revenue 42.3m / 45.7m) |
| TATA: 0.02 (NI -205.8m - CFO -210.9m) / TA 251.7m) |
| Beneish M-Score: -0.37 (Cap -4..+1) = D |
What is the price of EYPT shares?
Over the past week, the price has changed by -1.63%, over one month by -21.12%, over three months by +20.04% and over the past year by +100.91%.
Is EYPT a buy, sell or hold?
- StrongBuy: 9
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EYPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 36.1 | 171.3% |
| Analysts Target Price | 36.1 | 171.3% |
| ValueRay Target Price | 14.8 | 11.4% |
EYPT Fundamental Data Overview February 03, 2026
P/B = 6.1
Revenue TTM = 42.3m USD
EBIT TTM = -212.1m USD
EBITDA TTM = -210.0m USD
Long Term Debt = 21.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.25m USD (from shortTermDebt, last fiscal year)
Debt = 21.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -53.3m USD (from netDebt column, last quarter)
Enterprise Value = 936.6m USD (1.12b + Debt 21.3m - CCE 204.0m)
Interest Coverage Ratio = -15.1k (Ebit TTM -212.1m / Interest Expense TTM 14.0k)
EV/FCF = -4.38x (Enterprise Value 936.6m / FCF TTM -213.6m)
FCF Yield = -22.81% (FCF TTM -213.6m / Enterprise Value 936.6m)
FCF Margin = -504.5% (FCF TTM -213.6m / Revenue TTM 42.3m)
Net Margin = -486.0% (Net Income TTM -205.8m / Revenue TTM 42.3m)
Gross Margin = 94.08% ((Revenue TTM 42.3m - Cost of Revenue TTM 2.51m) / Revenue TTM)
Gross Margin QoQ = 25.36% (prev none%)
Tobins Q-Ratio = 3.72 (Enterprise Value 936.6m / Total Assets 251.7m)
Interest Expense / Debt = 0.07% (Interest Expense 14.0k / Debt 21.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -167.6m (EBIT -212.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.18 (Total Current Assets 216.1m / Total Current Liabilities 30.1m)
Debt / Equity = 0.11 (Debt 21.3m / totalStockholderEquity, last quarter 200.2m)
Debt / EBITDA = 0.25 (negative EBITDA) (Net Debt -53.3m / EBITDA -210.0m)
Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -53.3m / FCF TTM -213.6m)
Total Stockholder Equity = 270.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.47% (Net Income -205.8m / Total Assets 251.7m)
RoE = -76.13% (Net Income TTM -205.8m / Total Stockholder Equity 270.3m)
RoCE = -72.74% (EBIT -212.1m / Capital Employed (Equity 270.3m + L.T.Debt 21.3m))
RoIC = -61.99% (negative operating profit) (NOPAT -167.6m / Invested Capital 270.3m)
WACC = 9.25% (E(1.12b)/V(1.14b) * Re(9.42%) + D(21.3m)/V(1.14b) * Rd(0.07%) * (1-Tc(0.21)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 29.00%
Fair Price DCF = unknown (Cash Flow -213.6m)
EPS Correlation: 11.36 | EPS CAGR: 17.89% | SUE: 4.0 | # QB: 1
Revenue Correlation: -33.87 | Revenue CAGR: -48.39% | SUE: -0.42 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.70 | Chg30d=-0.032 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.82 | Chg30d=-0.057 | Revisions Net=-1 | Growth EPS=+6.3% | Growth Revenue=-85.0%